Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

(2019) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ovarian cancer statistics, 2018

(2018) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

In VitroandIn VivoActivity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers

(2018) Gary Altwerger et al.   MOLECULAR CANCER THERAPEUTICS

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

(2018) David M. Goldenberg et al.   Oncotarget

SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression

(2017) Gulden Menderes et al.   GYNECOLOGIC ONCOLOGY

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

(2017) Rebecca Suk Heist et al.   JOURNAL OF CLINICAL ONCOLOGY

Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells

(2017) Bin Wu et al.   Experimental and Therapeutic Medicine

Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas

(2017) Peng Xu et al.   Cancer Management and Research

Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma

(2016) Bishoy Faltas et al.   Clinical Genitourinary Cancer

Ovarian cancer

(2016) Ursula A. Matulonis et al.   Nature Reviews Disease Primers

Targeted therapy in cancer

(2015) Apostolia-Maria Tsimberidou   CANCER CHEMOTHERAPY AND PHARMACOLOGY

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

(2015) A. N. Starodub et al.   CLINICAL CANCER RESEARCH

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

(2015) David M. Goldenberg et al.   Oncotarget

T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo

(2014) Diana P. English et al.   Cancer Medicine

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

(2013) Dana M. Roque et al.   CLINICAL & EXPERIMENTAL METASTASIS

Overexpression of TROP2 Predicts Poor Prognosis of Patients with Cervical Cancer and Promotes the Proliferation and Invasion of Cervical Cancer Cells by Regulating ERK Signaling Pathway

(2013) Ting Liu et al.   PLoS One

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

(2013) S. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Upregulation of Trop-2 quantitatively stimulates human cancer growth

(2012) M Trerotola et al.   ONCOGENE

Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody

(2011) Joyce Varughese et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody

(2011) Joyce Varughese et al.   GYNECOLOGIC ONCOLOGY

Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients

(2010) Eliana Bignotti et al.   EUROPEAN JOURNAL OF CANCER

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

(2009) K El-Sahwi et al.   BRITISH JOURNAL OF CANCER

Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer

(2008) Youqing Liu et al.   CANCER LETTERS